Same Indication

Ipilimumab vs Ziprasidone Mesylate

Ipilimumab vs Ziprasidone Mesylate: Overview

This comparison examines the pharmacological differences between Ipilimumab and Ziprasidone Mesylate.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days.

Chemical Properties

Type: Ipilimumab — Antibody; Ziprasidone Mesylate — Small molecule.